Mercaptopurine

Mercaptopurine

Error creating thumbnail: File missing
Clinical data
Pregnancy category	?,(Increased Risk of Abortion)
Routes of administration	Oral
ATC code	L01BB02 (WHO)
Legal status
Legal status	?
Pharmacokinetic data
Bioavailability	5 to 37%
Metabolism	?
Elimination half-life	60 to 120 min., longer for its active metabolites
Excretion	Renal
Identifiers
IUPAC name 3,7-dihydropurine-6-thione
CAS Number	50-44-2
PubChem CID	667490
DrugBank	APRD01096.txt
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C5H4N4S
Molar mass	152.181 g/mol

WikiDoc Resources for Mercaptopurine
Articles
Most recent articles on Mercaptopurine Most cited articles on Mercaptopurine Review articles on Mercaptopurine Articles on Mercaptopurine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mercaptopurine Images of Mercaptopurine Photos of Mercaptopurine Podcasts & MP3s on Mercaptopurine Videos on Mercaptopurine
Evidence Based Medicine
Cochrane Collaboration on Mercaptopurine Bandolier on Mercaptopurine TRIP on Mercaptopurine
Clinical Trials
Ongoing Trials on Mercaptopurine at Clinical Trials.gov Trial results on Mercaptopurine Clinical Trials on Mercaptopurine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mercaptopurine NICE Guidance on Mercaptopurine NHS PRODIGY Guidance FDA on Mercaptopurine CDC on Mercaptopurine
Books
Books on Mercaptopurine
News
Mercaptopurine in the news Be alerted to news on Mercaptopurine News trends on Mercaptopurine
Commentary
Blogs on Mercaptopurine
Definitions
Definitions of Mercaptopurine
Patient Resources / Community
Patient resources on Mercaptopurine Discussion groups on Mercaptopurine Patient Handouts on Mercaptopurine Directions to Hospitals Treating Mercaptopurine Risk calculators and risk factors for Mercaptopurine
Healthcare Provider Resources
Symptoms of Mercaptopurine Causes & Risk Factors for Mercaptopurine Diagnostic studies for Mercaptopurine Treatment of Mercaptopurine
Continuing Medical Education (CME)
CME Programs on Mercaptopurine
International
Mercaptopurine en Espanol Mercaptopurine en Francais
Business
Mercaptopurine in the Marketplace Patents on Mercaptopurine
Experimental / Informatics
List of terms related to Mercaptopurine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Mercaptopurine (also called 6-Mercaptopurine, 6-MP or its brand name Purinethol) is an immunosuppressive drug used to treat leukemia. It is also used for pediatric non-Hodgkin's lymphoma, polycythemia vera, psoriatic arthritis, and inflammatory bowel disease (such as Crohn's Disease and ulcerative colitis).

Adverse reactions

Some of the adverse reactions of taking Mercaptopurine might include diarrhea, nausea, vomiting, loss of appetite, stomach/abdominal pain, weakness, skin rash, darkening of the skin, or hair loss. Serious adverse reactions include mouth sores, fever, sore throat, easy bruising or bleeding, pinpoint red spots on the skin, yellowing of eyes or skin, dark urine, painful or difficult urination. Unlikely but serious side effects include: black or tarry stools (melena), bloody stools, and bloody urine.

Symptoms of allergic reaction to Mercaptopurine include rash, itching, swelling, dizziness, trouble breathing.

Mercaptopurine causes myelosuppression, suppressing the production of white blood cells. It may be toxic to bone marrow. Weekly blood counts are recommended for patients on mercaptopurine. The patient should stop taking the medication at least temporarily if there is an unexplained, abnormally large drop in white blood cell count, or any other blood count.

Patients who exhibit myelosuppression or bone marrow toxicity should be tested for Thiopurine methyltransferase (TPMT) enzyme deficiency. Patients with TPMT deficiency are much more likely to develop dangerous myelosuppression. In such patients it may be possible to continue using mercaptopurine, but at a lower dose.

Precautions

Mercaptopurine can lower the body's ability to fight off infection. Those taking mercaptopurine should get permission from a doctor in order to receive immunizations and vaccinations. It is also recommended that while on the drug one should avoid those who have recently received oral polio vaccine.

This drug is traditionally not recommended during pregnancy but this issue has been debated and current evidence indicates that pregnant women on the drug show no increase in fetal abnormalities. However, women receiving mercaptopurine during the first trimester of pregnancy have an increased incidence of abortion. Davis et al 1999 found that mercaptopurine, compared to methotrexate, was ineffective as a single-agent abortifacient; every woman in the mercaptopurine arm of the study had fetal cardiac activity at follow-up (two weeks later) and was given a suction abortion.

Mercaptopurine causes changes to chromosomes in animals and humans. In mice these changes have given rise to lethal mutations. Therefore the drug has the potential to be cancer causing in humans.

See also

• azathioprine

References

• FDA Label, Mercaptopurine (PDF)